The molecular pathogenesis of Equine rhinitis A virus, a major respiratory pathogen of horses. The equine industry in Australia is worth $15 billion a year. Equine respiratory disease costs Victoria, alone, $5-10 million per year. Equine rhinitis A virus is a major cause of acute febrile respiratory disease in horses. This project aims to develop an infectious clone to study the pathogenesis of the disease, and subunit antigens for use as vaccines. These reagents will increase our understand ....The molecular pathogenesis of Equine rhinitis A virus, a major respiratory pathogen of horses. The equine industry in Australia is worth $15 billion a year. Equine respiratory disease costs Victoria, alone, $5-10 million per year. Equine rhinitis A virus is a major cause of acute febrile respiratory disease in horses. This project aims to develop an infectious clone to study the pathogenesis of the disease, and subunit antigens for use as vaccines. These reagents will increase our understanding of the pathogenesis of ERAV and will lead to experimental vaccines which will be tested in horses.Read moreRead less
Inhibitors Of Bacterial Protein Synthesis - A New Class Of Antibiotics
Funder
National Health and Medical Research Council
Funding Amount
$120,000.00
Summary
Pioneering work by CSIRO scientists has identified specific peptide motifs in the DNA replication machinery of bacteria that are critical for the correct functioning of the organism. In collaboration with CI Alewood potent (Kd ~ nM) lead compounds that inhibit bacterial DNA replication have been designed and synthesised. Through the application of a number of novel bioinformatics approaches to the analysis of the complete genome sequences of bacteria, the key sites of interaction of a number of ....Pioneering work by CSIRO scientists has identified specific peptide motifs in the DNA replication machinery of bacteria that are critical for the correct functioning of the organism. In collaboration with CI Alewood potent (Kd ~ nM) lead compounds that inhibit bacterial DNA replication have been designed and synthesised. Through the application of a number of novel bioinformatics approaches to the analysis of the complete genome sequences of bacteria, the key sites of interaction of a number of protein families (DNA synthesis and repair enzymes) with the beta subunit of bacterial DNA Polymerase III have been identified. The nature of the sites, and preliminary experimental data, suggests that the approach will be generally applicable to all species of bacteria. In addition a wide range of novel assays for the identification of inhibitors of the interaction of proteins with the beta subunit have been developed. In this proposal we wish to demonstrate that our in vitro nanomolar inhibitors of the beta subunit can inhibit bacterial cell growth. The development program proposes to develop methods and strategies to gain bacterial cell entry of inhibitors of the interaction of proteins with the beta subunit of bacterial DNA Polymerase III. Proof of concept will be demonstrated by inhibition of bacterial cell growth. Stable compounds with good binding characteristics and able to be taken up by cells will be developed based on structure-function assay results, structural studies and modelling of inhibitors bound to the target. Antimicrobial activity of compounds will be demonstrated in standard FDA approved NCLLS (National Centre of Clinical Laboratory Standards USA) tests. Spectrum of activity will be demonstrated by testing compounds against bacterial species representative of the range of pathogenic organisms in standard FDA assays.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989341
Funder
Australian Research Council
Funding Amount
$690,000.00
Summary
Advanced NanoBiomaterials Imaging Facility. The convergence of nanotechnology with biotechnology offers unprecedented opportunities to prepare nanomaterials with defined structure and function on the nanometre scale. However, the small length scales involved in nanomaterials present challenges in their characterisation, and in turn, their interaction with biological systems. The Advanced NanoBiomaterials Imaging Facility will provide state-of-the-art equipment for examining the properties of nan ....Advanced NanoBiomaterials Imaging Facility. The convergence of nanotechnology with biotechnology offers unprecedented opportunities to prepare nanomaterials with defined structure and function on the nanometre scale. However, the small length scales involved in nanomaterials present challenges in their characterisation, and in turn, their interaction with biological systems. The Advanced NanoBiomaterials Imaging Facility will provide state-of-the-art equipment for examining the properties of nanomaterials and their interaction with biosystems. The equipment will facilitate the development of new materials that are expected to underpin advances in drug delivery, diagnostics and implant devices, further strengthening Australia's strong reputation in these areas.Read moreRead less
A New Recombinant Subunit Vaccine against Equine Herpesviruses 1 and 4. Equine herpesviruses 1 and 4 (EHV-1 and EHV-4) cause respiratory disease, abortion and myeloencephalitis in horse populations worldwide. Despite extensive use of whole virus vaccines, these two viruses continue to circulate among Australian horses and are a continuing threat to brading, and to racing performance. The current vaccines are expensive and are marked in Australia by an overseas company. The project will assess th ....A New Recombinant Subunit Vaccine against Equine Herpesviruses 1 and 4. Equine herpesviruses 1 and 4 (EHV-1 and EHV-4) cause respiratory disease, abortion and myeloencephalitis in horse populations worldwide. Despite extensive use of whole virus vaccines, these two viruses continue to circulate among Australian horses and are a continuing threat to brading, and to racing performance. The current vaccines are expensive and are marked in Australia by an overseas company. The project will assess the ability of a new subunit vaccine produced by recombinant DNA technology to 1) provide horses with high levels of protective immune responses and 2) to prevent or limit EHV-1 and EHV-4 infection following experimental challenge.Read moreRead less
Innovation Management Strategies and Practices to Accelerate the Commercialisation Process in the Biotechnology Industry. The innovation cycle is a complex and misunderstood area of management, particularly in the Biotechnology Industry where the innovation cycle can take up to 15 years. The management literature provides anecdotal information, however, lacks theoretical models which provide guidance to Managers on how to shorten the innovation process. Therefore, the aim of this PhD research, ....Innovation Management Strategies and Practices to Accelerate the Commercialisation Process in the Biotechnology Industry. The innovation cycle is a complex and misunderstood area of management, particularly in the Biotechnology Industry where the innovation cycle can take up to 15 years. The management literature provides anecdotal information, however, lacks theoretical models which provide guidance to Managers on how to shorten the innovation process. Therefore, the aim of this PhD research, which is "a world first", is to develop and test an innovation cycle model through quantitative and qualitative research. Expected outcomes include developing a valid and reliable model for measuring and predicting relationships between innovation practice and innovation performance and developing case studies for teaching purposes.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0775758
Funder
Australian Research Council
Funding Amount
$587,000.00
Summary
A Mass Spectrometry and Proteomics Facility. This facility will support a large group of nationally and internationally recognised scientists working on a range of projects in the National Interest: the role of apoptosis in normal and diseased cells, mitochondrial biogenesis and genetic diseases resulting from defects in mitochondrial function, malarial vaccine and drug development, plant biotehnology, design and synthesis of drugs, DNA-anticancer drug interactions and biomarker discovery. By su ....A Mass Spectrometry and Proteomics Facility. This facility will support a large group of nationally and internationally recognised scientists working on a range of projects in the National Interest: the role of apoptosis in normal and diseased cells, mitochondrial biogenesis and genetic diseases resulting from defects in mitochondrial function, malarial vaccine and drug development, plant biotehnology, design and synthesis of drugs, DNA-anticancer drug interactions and biomarker discovery. By supporting this wide range of well funded researh, the mass spectrometry facility will support the emerging Biotechnology sector and National Research Priorities.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0561042
Funder
Australian Research Council
Funding Amount
$852,705.00
Summary
Establishing a high-throughput Protein Production Unit. We seek to establish a world class high-throughput (H-T) protein production unit, the first of its kind in Australia. Throughout the unit robotic technology will be used to build and test protein expression systems as well as drive large scale protein production. The product of the unit will be high quality, pure protein, effective expression systems and world class research. The unit will act as a centre for research into H-T protein ex ....Establishing a high-throughput Protein Production Unit. We seek to establish a world class high-throughput (H-T) protein production unit, the first of its kind in Australia. Throughout the unit robotic technology will be used to build and test protein expression systems as well as drive large scale protein production. The product of the unit will be high quality, pure protein, effective expression systems and world class research. The unit will act as a centre for research into H-T protein expression technology, will underpin the finest biological research, provide the basis for large "structural genomic" type approaches to biological problems and provide a wealth of projects for the Australian synchrotron.Read moreRead less
Plant Cells for Improved Oral Delivery of Vaccines. The pharmaceutical industry is ever assessing methods of improved delivery of their valuable vaccines, pharmaceuticals and nutraceuticals. The oral route increases ease of delivery, is less expensive, and has increased patient compliance. It may also allow vaccination of free-ranging animal populations that may otherwise go untreated. Optimizing oral delivery of plant-made, valuable proteins will therefore have broad ramifications to animal and ....Plant Cells for Improved Oral Delivery of Vaccines. The pharmaceutical industry is ever assessing methods of improved delivery of their valuable vaccines, pharmaceuticals and nutraceuticals. The oral route increases ease of delivery, is less expensive, and has increased patient compliance. It may also allow vaccination of free-ranging animal populations that may otherwise go untreated. Optimizing oral delivery of plant-made, valuable proteins will therefore have broad ramifications to animal and human health industries, enhancing use of existing valuable compounds and creating opportunities for new compounds and user groups including wild and domesticated animals.Read moreRead less
Efficient organelle transformation. Chloroplasts and mitochondria are the powerhouses of plant and animal cells. Ability to express introduced genes in these organelles has enormous biotechnological potential in agriculture and medicine, but practical development has been almost stalled for 15 years by very low transformation efficiency. Plastid transformation is today routine only in tobacco; and mitochondrial transformation has been achieved only in yeasts and algae. We have developed a soluti ....Efficient organelle transformation. Chloroplasts and mitochondria are the powerhouses of plant and animal cells. Ability to express introduced genes in these organelles has enormous biotechnological potential in agriculture and medicine, but practical development has been almost stalled for 15 years by very low transformation efficiency. Plastid transformation is today routine only in tobacco; and mitochondrial transformation has been achieved only in yeasts and algae. We have developed a solution, and achieved the key technical requirements for proof of concept. This collaboration between industry, government and university partners will deliver key Australian-owned IP, for environmentally-friendly plant biofactories, and for treatment of mitochondrial genetic disorders.Read moreRead less
Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccine ....Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccines delivered with a Nanopatch will require less refrigeration than conventional vaccines and can be safely administered by individuals without medical training, making the benefits of vaccination accessible to more people more cheaply, even in remote areas.Read moreRead less